p16Ink4a-expressing cells, both epithelial and mesenchymal, have been found to be increased in lung samples of individuals with IPF (4, 5, 23), and senolytic clearance by pharmacologic approaches have been proposed as a potential treatment for IPF (24). Here, CDKN2A is linked to idiopathic pulmonary fibrosis.